U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H24ClN3O2.C4H4O4
Molecular Weight 489.949
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CLEBOPRIDE MALEATE

SMILES

OC(=O)\C=C/C(O)=O.COC1=C(C=C(Cl)C(N)=C1)C(=O)NC2CCN(CC3=CC=CC=C3)CC2

InChI

InChIKey=BCVIWCRZYPHHMQ-BTJKTKAUSA-N
InChI=1S/C20H24ClN3O2.C4H4O4/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14;5-3(6)1-2-4(7)8/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25);1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI
Clebopride is a dopamine antagonist drug. It is used to treat functional gastrointestinal disorder such as nausea or vomiting. Unchanged parent drug was the most abundant compound in human urine. Major metabolites included the hydroxylation at benzyl group to yield carbinolamine and its further N-dealkylation product, and the piperidine ring hydroxylation/oxidation metabolite (a lactam).

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CLEBOPRIDE

Approved Use

Clebopride is used in the treatment of stomach ulcer, inflammation of stomach and intestine, indigestion. It also reduces the symptoms like excessive air accumulation in gut, nausea and vomiting associated with stomach discomfort.
PubMed

PubMed

TitleDatePubMed
Synthesis and pharmacological properties of a series of antidopaminergic piperidyl benzamides.
1977 Mar
[Clebopride, a new orthopramide with potent and selective central antidopaminergic properties].
1978 Apr
[Drug-induced extrapyramidal syndrome. Apropos of 22 cases].
1987 Feb
NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
1993 Jun 11
Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.
2002
Dopamine antagonists during parturition disrupt maternal care and the retention of maternal behavior in rats.
2002 Nov
Etiological and therapeutical observations in a case of belly dancer's dyskinesia.
2006 Sep
Prokinetic drug utility in the treatment of gastroesophageal reflux esophagitis: a systematic review of randomized controlled trials.
2007
Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac repolarization.
2007 Jan-Feb
Acute oculogyric crisis in a patient taking clebopride.
2008
[A new method of investigation of "child's" behavior (infant-mother attachment) of newborn rats].
2010 Mar-Apr
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Patents

Patents

Sample Use Guides

500 mcg 3 times/day.
Route of Administration: Oral
Clebopride at 10 uM significantly decreased the Vmax of phase 0 depolarization in isolated rabbit Purkinje fiber and significantly prolonged the action potential duration at 90% repolarization, whereas the action potential duration at 50% repolarization was not prolonged. For hERG potassium channel currents in human ether-à-go-go-related gene (hERG)-stably transfected Chinese hamster ovarian (CHO) cells the IC50 value was 0.62 uM.
Name Type Language
CLEBOPRIDE MALEATE
Common Name English
4-(4-AMINO-5-CHLORO-2-METHOXYBENZAMIDO)-1-BENZYLPIPERIDINE MALEATE SALT
Common Name English
CLEBOPRIDE MALEATE SALT
Common Name English
CLEBOPRIDE HYDROGEN MALEATE
Common Name English
Code System Code Type Description
EVMPD
SUB01334MIG
Created by admin on Fri Dec 15 16:59:10 GMT 2023 , Edited by admin on Fri Dec 15 16:59:10 GMT 2023
PRIMARY
RXCUI
236701
Created by admin on Fri Dec 15 16:59:10 GMT 2023 , Edited by admin on Fri Dec 15 16:59:10 GMT 2023
PRIMARY RxNorm
PUBCHEM
6420010
Created by admin on Fri Dec 15 16:59:10 GMT 2023 , Edited by admin on Fri Dec 15 16:59:10 GMT 2023
PRIMARY
SMS_ID
100000087947
Created by admin on Fri Dec 15 16:59:10 GMT 2023 , Edited by admin on Fri Dec 15 16:59:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID6047787
Created by admin on Fri Dec 15 16:59:10 GMT 2023 , Edited by admin on Fri Dec 15 16:59:10 GMT 2023
PRIMARY
FDA UNII
P42041X5SU
Created by admin on Fri Dec 15 16:59:10 GMT 2023 , Edited by admin on Fri Dec 15 16:59:10 GMT 2023
PRIMARY
MESH
C014417
Created by admin on Fri Dec 15 16:59:10 GMT 2023 , Edited by admin on Fri Dec 15 16:59:10 GMT 2023
PRIMARY
CAS
84370-95-6
Created by admin on Fri Dec 15 16:59:10 GMT 2023 , Edited by admin on Fri Dec 15 16:59:10 GMT 2023
PRIMARY